AiVita Biomedical, Inc.

AiVita Biomedical, Inc. specializes in personalized vaccine development, addressing cancer and infectious diseases through innovative pan-antigenic targeting techniques, aimed at enhancing treatment efficacy and patient outcomes. Founded in 2016 and headquartered in Irvine, US, AiVita Biomedical, Inc. focuses on personalized vaccine solutions.

The company has secured a total of USD 25. 00 mn in funding through 6 deals, with its most recent funding round being Series B on December 29, 2020. The CEO, Hans Keirstead, leads the company in advancing its mission. AiVita Biomedical develops personalized vaccines that focus on combating cancer and infectious diseases.

Their offerings include a cancer vaccine that targets all neoantigens, improving efficacy against evolving cancer mutations, and a multi-pathogen vaccine kit designed to boost adaptive immunity against various pathogens. These products are marketed to healthcare providers, research institutions, and patients across North America, Europe, and select parts of Asia, contributing to global healthcare efforts. AiVita Biomedical generates revenue primarily through partnerships and licensing agreements with healthcare institutions and research organizations. The company engages in direct business-to-business transactions for its personalized vaccine solutions, creating agreements tailored to specific therapeutic programs and ensuring various pricing models for clients utilizing its products in clinical settings.

AiVita Biomedical plans to leverage the USD 25. 00 mn raised in Series B funding to expand its product offerings and market reach. Upcoming initiatives include the design of new vaccines targeting additional cancer types and emerging infectious diseases. The company aims to penetrate new geographic markets in Asia and Europe by the end of 2023, aligning with its strategic growth objectives.